15 Amendments of Luke Ming FLANAGAN related to 2017/2254(INI)
Amendment 6 #
Draft opinion
Paragraph 1
Paragraph 1
1. Stresses that antimicrobial resistance (AMR) is a critical global health issue that requires proactive, coordinated action; underlines the importance of taking a holistic approach to tackling AMR through the one-health approach, by ensuring coherence and coordination between human health, animal health, food production and the environment, as it can serve as a reservoir of antibiotic- resistance genes;
Amendment 18 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls on the Commission and the Member States to take an ambitious approach to ensuring that the targets set out in their respective Action Plans are fully and effectively achieved in a coordinated manner across the EU to ensure their effectiveness, and to strictly monitor the results that have been achieved;
Amendment 61 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Firmly believes that the most effective means of combatting AMR which is linked to the intensification of farming is the promotion of short supply chains in the food industry and the creation of local quality brands, these can bring benefits such as; Improved negotiating positions for farmers; These supply chains offer farmers greater power during negotiations, especially during those with retailers, Increased communication between producer and consumer; Short supply chains can lead to job creation, especially in rural areas, Reduced transportation costs; Short supply chains typically serve a local area, reducing the energy costs, transportation costs, and CO2 emissions, Increased transparency; It’s easier to make short supply chains with few or no intermediaries transparent than it is longer and more complex ones, Reduced risk; A short supply chain reduces the risk of damage, contamination, Increased quality; Doing business and transporting goods locally increases their overall quality by reducing the need for freezing and use of preservatives, Greater profits; Short supply chains offer farmers with greater profits while keeping the end-price more or less the same for consumers;
Amendment 67 #
Motion for a resolution
Recital E a (new)
Recital E a (new)
Ea. whereas nature provides us with a plethora of powerful antibiotics, a source which could be harnessed to a far greater degree than is presently the case;
Amendment 88 #
Draft opinion
Paragraph 6
Paragraph 6
6. Calls on the Commission and the Member States to ensure adequate funding for on-farm investments, such as in quality housing, ventilation, cleaning, disinfection, the use and application of manures on land, vaccination and bio-security;
Amendment 99 #
Draft opinion
Paragraph 7
Paragraph 7
7. Emphasises the crucial role of education and training programmes ins, calls for funding to be made available to raisinge awareness about antimicrobial resistance and the prudent use of antimicrobials in veterinary medicine for farmers and those involved in livestock farming;
Amendment 133 #
Draft opinion
Paragraph 9
Paragraph 9
9. Notes that the use of antibiotics as growth promoters in food-producing animals has been banned in the EU since 2006; calls on the Commission to enforce this ban as an ex ante conditionality to all food imports from third countries through Free Trade Agreements;
Amendment 152 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Calls on the Commission to explore the possibility of expanding the development and use of natural antibiotics;
Amendment 168 #
6. Emphasises that prevention is better than cure; infection prevention, biosecurity measures and control practices are critical in the control of all infectious microorganisms as they reduce the need for antimicrobials and consequently opportunities for microorganisms to develop and spread resistance;
Amendment 183 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Calls on the Commission and the Member States to develop public health messages to raise public awareness on the cause and effect of Antimicrobial Resistance (AMR) and in doing so, to promote a change in behaviour towards the use of antibiotics; underlines the importance of promoting ‘health literacy’, since it is crucial that patients understand healthcare information and are able to follow treatment instructions accurately;
Amendment 216 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Is aware that the cost of rapid diagnostic tools (RDT) may exceed the price of antibiotics; calls on the Commission to propose incentives for the industry to develop effective and efficient testing methods and calls on health insurance carriers to cover the extra cost arising from the use of RDT, given the long-term benefits of preventing the unnecessary use of antimicrobials, and the subsequent major cost savings for the health insurance industry;
Amendment 232 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Calls on the Commission and the Member States to restrict or stop the sale of antibiotics by those doctors or veterinarians who over-prescribe them;
Amendment 255 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Highlights the value of vaccines in combating AMR; highlights further the need to fully inform and reassure the public on the safety of those vaccines through industry-independent studies, given that the lower the uptake of vaccines, the greater the risk of the spread of that disease; recommends integration of targets for life-long vaccination as a key element of national action plans on AMR;
Amendment 372 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
21 a. calls on the Commission to ensure that in any situation in which it has invested EU funds, the possibility for excess private profit extraction is minimised;
Amendment 418 #
Motion for a resolution
Paragraph 26
Paragraph 26
26. Notes that AMR is of serious concern in many poverty-related and neglected diseases (PRNDs), including HIV/AIDS, malaria and tuberculosis (TB); highlights that about 29 % of deaths caused by AMR are due to drug-resistant TB, and calls on the Commission and the Member States to increase their support to research for health tools to address PRNDs affected by AMR and to ensure that, should those new health tools be developed, prices of those new drugs are kept at a reasonable level;